2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Cytoskeleton
  4. Kinesin
  5. Kinesin Isoform
  6. Kinesin Inhibitor

Kinesin Inhibitor

Kinesin Inhibitors (46):

Cat. No. Product Name Effect Purity
  • HY-132840
    Sovilnesib
    		Inhibitor 99.89%
    Sovilnesib (AMG 650) is a potent, orally active kinesin-like protein KIF18A inhibitor with an IC50 value of 0.071 μM. Sovilnesib can be used for the research of cancer.
  • HY-101770
    BTB-1
    		Inhibitor 99.75%
    BTB-1 is a potent, selective and reversible mitotic motor protein Kif18A inhibitor with an IC50 of 1.69 μM.
  • HY-153065
    KIF18A-IN-6
    		Inhibitor 98.56%
    KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC50 of 0.016 μM against KIF18A microtubule-dependent ATPase activity.
  • HY-144894
    AM-5308
    		Inhibitor 99.26%
    AM-5308 is a potent kinesin KIF18A inhibitor (WO2021211549A1, C13).
  • HY-115570
    GW406108X
    		Inhibitor ≥98.0%
    GW406108X is a specific Kif15 (Kinesin-12) inhibitor with an IC50 of 0.82 uM in ATPase assays. GW406108X, a potent autophagy inhibitor, shows ATP competitive inhibition against ULK1 with a pIC50 of 6.37 (427 nM). GW406108X inhibits ULK1 kinase activity and blocks autophagic flux, without affecting the upstream signaling kinases mTORC1 and AMPK.
  • HY-115570A
    (Z/E)-GW406108X
    		Inhibitor
    (Z/E)-GW406108X is a mixture of different configurations of GW406108X (HY-115570). GW406108X is a specific Kif15 (Kinesin-12) inhibitor with an IC50 of 0.82 uM.
  • HY-162937
    KIF18A-IN-13
    		Inhibitor
    KIF18A-IN-13 (Compound 16) is an effective and orally active inhibitor of KIF18A with anticancer activity in vivo. KIF18A-IN-13 can be utilized for research in ovarian cancer.
  • HY-164978
    KIF18A-IN-14
    		Inhibitor
    KIF18A-IN-14 (Compound Example 81) is a KIF18A inhibitor. KIF18A-IN-14 is available in two forms, EX81-A and its enantiomer EX81-B. EX81-A and EX81-B inhibit OVCAR-3 cells viability with IC50s of 0-0.01 μM and 0.01-0.1 μM, respectively. KIF18A-IN-14 can be used in tumor (e.g. colon, breast, lung) studies.
  • HY-145034
    KIF18A-IN-1
    		Inhibitor 98.39%
    KIF18A-IN-1 is a mitotic kinesin KIF18A inhibitor extracted from patent WO2021026098A1 example 100-13. KIF18A-IN-1 exhibits anti-tumor activity.
  • HY-13224
    AZD4877
    		Inhibitor 98.15%
    AZD4877 is another isostere to Ispinesib (HY-50759)and also a kinesin spindle protein (Eg5) inhibitor with IC50 of 2 nM.AZD4877 arrests cell mitosis, leads to the formation of the monopolar spindle phenotype and induces apoptosis. AZD4877 inhibits circulating peripheral blood mononuclear cells (PBMCs) and has anti-cancer activity.
  • HY-153066
    KIF18A-IN-7
    		Inhibitor 98.09%
    KIF18A-IN-7 (Compound 22) is an orally active KIF18A inhibitor with an IC50 of 9.4 nM against KIF18A microtubule-dependent ATPase activity.
  • HY-162110
    AM-9022
    		Inhibitor 99.48%
    AM-9022 is an orally active, potent, selective KIF18A inhibitor that can be used for research on cancer.
  • HY-160441
    MC-Val-Cit-PAB-Ispinesib
    		Inhibitor 99.85%
    MC-Val-Cit-PAB-Ispinesib (Compound 509) is a potent inhibitor of Eg5. MC-Val-Cit-PAB-Ispinesib is a click chemistry reagent.
  • HY-145803
    KIF18A-IN-3
    		Inhibitor 99.30%
    KIF18A-IN-3 is a potent KIF18A inhibitor (IC50=61 nM). KIF18A-IN-3 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-3 can be used for researching cancer.
  • HY-15187A
    (R)-Filanesib
    		Inhibitor 98.80%
    (R)-Filanesib ((R)-ARRY-520) is the R-enantiomer of Filanesib (HY-15187). Filanesib is a synthetic kinesin spindle protein (KSP) inhibitor with an IC50 of 6 nM.
  • HY-118961
    SR31527 chloride
    		Inhibitor
    SR31527 chloride is a potent KIFC1 inhibitor with an IC50 value of 6.6 µM. SR31527 chloride decreases cell viability and colony formation.
  • HY-145802
    KIF18A-IN-2
    		Inhibitor 99.34%
    KIF18A-IN-2 is a potent KIF18A inhibitor (IC50=28 nM). KIF18A-IN-2 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-2 can be used for researching cancer.
  • HY-15187B
    Filanesib TFA
    		Inhibitor
    Filanesib TFA (ARRY-520 TFA) is a selective kinesin spindle protein (KSP) inhibitor, with an IC50 of 6 nM for human KSP. Filanesib TFA induces cell death by apoptosis in vitro. Filanesib TFA has potent anti-proliferative activity.
  • HY-101071
    (S)-Monastrol
    		Inhibitor
    (S)-Monastrol ((+)-Monastrol) is an allosteric inhibitor of the mitotic kinesin Eg5 that exhibits an antiproliferative effect against several cancer cell lines. (S)-Monastrol arrests mammalian cells in mitosis with monopolar spindles.
  • HY-14661
    SB-743921 free base
    		Inhibitor
    SB-743921 free base is a potent selective inhibitor of the mitotic kinesin KSP (Eg5), with a Ki of 0.1 nM. SB-743921 free base can induce mitotic arrest, block cell cycle progression, induce apoptosis, and can be used in the research of myeloma, leukemia and other diseases.